JPH045647B2 - - Google Patents

Info

Publication number
JPH045647B2
JPH045647B2 JP58501579A JP50157983A JPH045647B2 JP H045647 B2 JPH045647 B2 JP H045647B2 JP 58501579 A JP58501579 A JP 58501579A JP 50157983 A JP50157983 A JP 50157983A JP H045647 B2 JPH045647 B2 JP H045647B2
Authority
JP
Japan
Prior art keywords
naloxone
compounds
oral
endogenous
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58501579A
Other languages
English (en)
Japanese (ja)
Other versions
JPS59500418A (ja
Inventor
Mearii Jiin Kuriiku
Jatsuku Fuitsushuman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of JPS59500418A publication Critical patent/JPS59500418A/ja
Publication of JPH045647B2 publication Critical patent/JPH045647B2/ja
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pinball Game Machines (AREA)
  • Medicinal Preparation (AREA)
JP58501579A 1982-03-16 1983-03-14 胃腸能動作用障害を回復する方法 Granted JPS59500418A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35882082A 1982-03-16 1982-03-16
US46411083A 1983-02-04 1983-02-04
US464110FREGB 1983-02-04
US358820FREGB 1983-02-04

Publications (2)

Publication Number Publication Date
JPS59500418A JPS59500418A (ja) 1984-03-15
JPH045647B2 true JPH045647B2 (https=) 1992-02-03

Family

ID=27000205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58501579A Granted JPS59500418A (ja) 1982-03-16 1983-03-14 胃腸能動作用障害を回復する方法

Country Status (6)

Country Link
EP (1) EP0103636B1 (https=)
JP (1) JPS59500418A (https=)
CA (1) CA1212323A (https=)
DE (1) DE3381877D1 (https=)
IT (1) IT1212714B (https=)
WO (1) WO1983003197A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477457A (en) * 1982-10-28 1984-10-16 E. I. Du Pont De Nemours And Company Method for inducing anorexia using nalmetrene
DE3690457T1 (https=) * 1985-09-06 1987-08-06
ES2051742T3 (es) * 1987-09-10 1994-07-01 Univ Chicago Derivados cuaternarios de noroxi-morfina que mitigan las nauseas y la emesis.
DE19605590A1 (de) * 1996-02-15 1997-08-21 Inresa Arzneimittel Gmbh Verwendung eines transdermalen therapeutischen Naloxon-Systems (Naloxon TTS)
EP0914097B1 (en) * 1996-03-12 2002-01-16 Alza Corporation Composition and dosage form comprising opioid antagonist
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1041987B1 (en) 1997-12-22 2006-04-19 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
AU776567B2 (en) * 1999-11-01 2004-09-16 Evans, Brian K Composition for treatment of constipation and irritable bowel syndrome
NZ518684A (en) * 1999-11-29 2003-11-28 Adolor Corp Use of a peripheral mu opioid antagonist to treat or prevent ileus
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
IL160222A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
HUE032656T2 (en) 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006127633A2 (en) 2005-05-20 2006-11-30 Electrolyzer Corp. Acidic electrolyzed water production system and protection membrane
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
ES2464593T3 (es) * 2005-11-09 2014-06-03 Toray Industries, Inc. Agente terapéutico o profiláctico para trastornos funcionales digestivos
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
ES2749800T3 (es) * 2006-06-05 2020-03-23 Nalpropion Pharmaceuticals Llc Formulación de liberación sostenida de naltrexona
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
CL2008000905A1 (es) 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
CN110893181A (zh) 2012-06-06 2020-03-20 纳丙药业有限责任公司 治疗超重和肥胖症的方法
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス.エイ. 疼痛および腸内ディスバイオシスをもたらす疾患および/または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060086A (en) * 1958-07-21 1962-10-23 Abbott Lab Anti-diarrhea composition
US3254088A (en) 1961-03-14 1966-05-31 Lewenstein Morphine derivative
US3214341A (en) * 1962-01-15 1965-10-26 Feinstone Wolffe Harry Prolonged action medicament
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
NL297631A (https=) * 1963-06-03
US3320262A (en) 1964-09-22 1967-05-16 Lewenstein 14 hydroxy morphine and codeine carboxymethyloximes
US3896226A (en) 1971-11-26 1975-07-22 Lewinstein Evalina 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist
JPS5619323B2 (https=) * 1972-10-11 1981-05-07
GB1522480A (en) * 1975-10-31 1978-08-23 British Ind Sand Rendering
GB1593191A (en) * 1977-03-23 1981-07-15 Reckitt & Colmann Prod Ltd Derivatives of morphine
GB1587831A (en) * 1977-03-23 1981-04-08 Reckitt & Colmann Prod Ltd Morphine derivatives
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
IL56222A (en) * 1978-02-10 1981-11-30 Miles Lab 3-hydroxy(and methoxy)-17-substituted-8beta-ethyl-(and 8beta-methyl)-4,5alpha-epoxymorphinan-6-one compounds and their production
US4272541A (en) * 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4277605A (en) 1980-03-07 1981-07-07 Bristol-Myers Company Chemical compounds

Also Published As

Publication number Publication date
CA1212323A (en) 1986-10-07
JPS59500418A (ja) 1984-03-15
DE3381877D1 (de) 1990-10-18
EP0103636B1 (en) 1990-09-12
EP0103636A4 (en) 1986-03-04
EP0103636A1 (en) 1984-03-28
IT1212714B (it) 1989-11-30
IT8320106A0 (it) 1983-03-16
WO1983003197A1 (en) 1983-09-29

Similar Documents

Publication Publication Date Title
JPH045647B2 (https=)
US4987136A (en) Method for controlling gastrointestinal dysmotility
TW550070B (en) Pharmaceutical compositions as analgesics
KR940011246B1 (ko) 로라타딘, 이부프로펜 및 슈도에페드린을 함유하는 약제학적 조성물
US4316888A (en) Method and composition of reducing pain
JP6226916B2 (ja) 医薬組成物
Brogden et al. Naproxen: a review of its pharmacological properties and therapeutic efficacy and use
US4668684A (en) Combination of flupirtin and anticholinergic acting spasmolytic
JPH0469605B2 (https=)
CA2317793C (en) Laxative composition
CN1171741A (zh) 冻干的奥丹亚龙组合物
TW200528113A (en) Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives
JPS638084B2 (https=)
TW200427469A (en) Pharmaceutical compositions of varenicline
JPS61500728A (ja) 食欲低下用医薬組成物
IE42793B1 (en) Preparation for treatment of colitis
HU225779B1 (en) Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
CN110582278B (zh) 药物组合物及其用途
JPH11158066A (ja) イブプロフェン含有医薬製剤
WO2001049269A1 (en) Sustained-releasing anthelmintic compositions comprising praziquantel
JP7499028B2 (ja) 内服用医薬組成物
AU674016B2 (en) Remedy for inflammatory intestinal diseases
JP2000026313A (ja) 消化管運動抑制剤
RU2121347C1 (ru) Лекарственный препарат
RU2784057C1 (ru) Средство, обладающее спазмолитическим, противоязвенным и антацидным действием